Orlistat Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia

Inclusion criteria

(Items 1, 2, and 4 meet at the same time, and items 3 and 5 meet one of them)

• Obtain the informed consent of the subjects before any trial-related activities (including activities carried out to assess the eligibility of subjects);
• Men or women over the age of 18 at the time of screening;
• The diagnosis of hyperuricemia refers to the fasting of serum uric acid > 420umol/L (7 mg/dl) twice on different days under a normal purine diet.
• The weight meets the following requirements (a or b): a) BMI ≥ 25.0 kg/m2; b) waist circumference, female ≥ 85 cm, male ≥ 90 cm.
• Suffering from hyperuricemia and/or gout.-

Exclusion criteria

• Use of drugs that may affect uric acid within 1 month before enrollment, including; benzbromarone, allopurinol, febuxostat, etc.;
• Abnormal liver function, ALT and AST are more than 2.5 times the upper limit of normal;
• Other diseases that affect glucose and lipid metabolism: hyperthyroidism, hypothyroidism, hypercortisolism, etc.;
• Diabetic patients with poor blood sugar control: HbA1c>7%;
• Chronic kidney disease or severe renal impairment, according to eGFR grading <45mL/min/1.73m2;
• The life expectancy does not exceed 5 years;
• Female subjects who are pregnant or plan to become pregnant within the next 24 weeks;
• Those who are expected to be unable to complete the intervention follow-up in other circumstances;
• If other drugs are used in combination, the drug dose should be kept stable for three months before enrollment;
• Participated in other clinical trials within the past 4 weeks;
• Use of drugs that affect body weight within 3 months before screening, including: systemic steroids (intravenous, oral or intra-articular), tricyclic antidepressants, psychiatric drugs or sedatives (eg, imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid, valproic acid derivatives, lithium salt), etc.;
• Obesity caused by secondary diseases or drugs, including: elevated cortisol hormone (for example: Cushing's syndrome), obesity caused by pituitary and hypothalamus damage, obesity caused by reduction/discontinuation of weight loss drugs, etc.;
• Inability to complete the exercise and for other reasons, the researcher believes that it is not suitable to participate in this researcher.-